{
  "docId": "019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "docSlug": "6d754588aa25b32079af055d51113b03",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 38,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The chart is a box-and-whisker plot showing longitudinal data from baseline through 56 weeks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ca9a-70d9-9ba2-1d5f94361fe0/32",
  "deckHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "deckJsonHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0.json",
  "deckAnchorHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Plasma Arginine in Response to Pegzilarginase in Phase 1/2 & OLE Studies",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bced180e-7ecb-486d-bb62-9b7b90d583f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.6,
        "y": 0.2
      },
      "kind": "list",
      "text": "Baseline: Baseline plasma arginine on standard disease management was markedly elevated. 20 Week Analysis: Median plasma arginine was 112µM, reduction was 277µM. 56 Week Analysis: Median plasma arginine was 99µM, 10/13 patients in normal range, 13/13 in target range.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f2664d0-72e3-4a11-8aa3-78aa88e926f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "OLE – Open-label extension. 1 Diaz, GA, et al, J Inherit Metab Dis. 2021;44:847-856; 2 Diaz, GA et al, Presented at 2020 European Academy of Neurology Annual Meeting",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "714b055b-df3a-41b8-9c92-1dc275b085cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Pegzilarginase Significantly and Sustainably Reduces Plasma Arginine Levels in Phase 1/2 & OLE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b7bf67e-6ad9-4e1a-a769-2b36a6ea9c0e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 38,
      "from": 3,
      "beatId": "e469074b-5500-4414-8b81-ef0652ee8a7d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 3-38 present various traction metrics, including clinical trial results and financial summaries",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}